Thousands of men in England with advanced prostate cancer are set to benefit from a newly approved life-extending treatment, following a recommendation by the National Institute for Health and Care Excellence (NICE). The drug darolutamide, also known by its brand name Nubeqa, will be available on the NHS for patients with metastatic hormone-sensitive prostate cancer starting on October 24. NICE has endorsed its use in combination with standard hormone therapy, offering a new therapeutic option for those in need.
How Darolutamide Works
Darolutamide works by blocking the action of hormones that facilitate the growth and spread of prostate cancer cells. Developed by Bayer, the treatment involves taking two tablets twice a day, in combination with androgen deprivation therapy (ADT), a hormone treatment designed to lower testosterone levels. This combination has shown promising results in clinical trials, demonstrating its effectiveness in extending survival and improving the quality of life for patients.
Eligibility and Expected Impact
Prostate cancer affects approximately 55,000 men in England each year, with up to 6,000 patients estimated to be eligible for this new combination therapy, according to NICE. In cases where prostate cancer has metastasized, treatment typically involves ADT or a combination of ADT and other medications. Clinical evidence indicates that adding darolutamide to ADT significantly improves outcomes, matching or surpassing the effectiveness of other existing treatment combinations already approved by NICE.
Key Statements from Health Officials
Helen Knight, the director of medicines evaluation at NICE, expressed her satisfaction with the new treatment option. She said, “I’m pleased we can recommend this new combination treatment which provides another much-needed option for people with metastatic hormone-sensitive prostate cancer.” Knight emphasized that the goal is to ensure that effective treatments like darolutamide are made available swiftly to those who need them, ultimately improving both the longevity and quality of life for patients.
Peter Johnson, national clinical director for cancer at NHS England, also welcomed the approval, noting, “With several proven therapies already available on the NHS, this approval gives clinicians and their patients more flexibility to choose the approach best suited to individual circumstances and clinical needs.” The flexibility to select a treatment that is tailored to a patient’s specific condition is a crucial aspect of improving patient outcomes.
Cost Agreement and Availability
In a move that will further increase accessibility, Bayer has entered into a confidential commercial arrangement with the NHS to offer darolutamide at a discounted price. This agreement aims to ensure that the treatment is affordable and accessible to those who need it, making it a viable option for many men diagnosed with metastatic prostate cancer.
Conclusion
The approval of darolutamide marks a significant step forward in the treatment of metastatic hormone-sensitive prostate cancer. By offering patients a new, more effective treatment option, the NHS aims to improve survival rates and enhance the quality of life for thousands of men across England.
Related topics
8 Myths About Prostate Cancer Testing That Could Be Putting You at Risk
GPs Urged to Lead ADHD Test Reform in the NHS
Breakthrough Study Reveals Potential mRNA Vaccine Strategy Against Tuberculosis
